Leerink Partners Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $159
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners maintains a Market Perform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $138 to $159.
June 25, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has maintained its Market Perform rating on Alnylam Pharmaceuticals and increased the price target from $138 to $159.
The increase in the price target from $138 to $159 by Leerink Partners suggests a positive outlook for Alnylam Pharmaceuticals. Although the rating remains Market Perform, the higher price target indicates potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100